About Emmes
Emmes is a Healthcare company based in United States founded in 1977, and was acquired by New Mountain Capital in June 2022. Outsourced contract research organization services are provided to clients. The company has 126 employees. Emmes has completed 7 acquisitions, including Casimir, Clinical Edge and Essex Management. Its website emmes.com draws about 57 thousand monthly visits. Its Indian entity Emmes Services Private Limited reported revenue of ₹81.85 Cr. Emmes offers products and services including Biostatistics, Clinical Data Management, and Clinical Trial Management. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its competitors include Celgene, Syneos Health and Medelis WCCT Global; 2 of its 3 listed competitors have raised funding.
Company details
Emmes was founded in 1977 and is headquartered in the United States. Operations focus on the healthcare sector, where clinical research services are delivered on an outsourced basis. Support is extended to pharmaceutical, biotechnology, and medical device industries through trial management, data analysis, and regulatory compliance. Activities are conducted primarily within North America, with services tailored to various therapeutic areas.
- Headquarters United States
- Employees 126
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website emmes.com
- Social LinkedIn X
- Acquired by New Mountain Capital (Jun 2022)
- Legal Name Emmes Services Private Limited
- Date of Incorporation 24 Apr, 2006
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹81.85 Cr
FY 2025 · +40% YoY
- Indian entity net profit₹21.56 Cr
FY 2025 · 26% margin
- Indian entity EBITDA₹30.54 Cr
FY 2025 · 37% margin
- Latest Funding Round$224.15K (USD), Grant
Mar 2022
- InvestorsHHS
& 3 more
- Employee Count126
- Investments & AcquisitionsCasimir
& 6 more
- Acquired byNew Mountain Capital
(Jun 2022)
Associated legal entities of Emmes
Emmes operates through Emmes Services Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Emmes Services Private Limited CIN U72200KA2006FTC039089 | Active | 24 Apr 2006 | Bangalore, Karnataka | ₹81.9 Cr | 126 | 3 | View details |
Products & Services of Emmes
Emmes offers a comprehensive portfolio of products and services, including Biostatistics, Clinical Data Management, and Clinical Trial Management.
Statistical services for managing clinical trial data
Services for organizing and securing clinical research data
End-to-end management of clinical trials and studies
Funding Insights of Emmes
- Total Rounds 12
- Last Round Grant — $224,149
- First Round $3.41M
(Mar 2007)
- Investors Count 3
Latest 10 of 12 funding rounds of Emmes with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | $224,149 | Grant | – | – | |
| Mar 2019 | Private Equity Round | – | Behrman Capital | – | |
| May 2018 | $1.14M | Grant | – | – | |
| Feb 2018 | $9.41M | Grant | – | – | |
| Sep 2016 | $1.06M | Grant | – | – | |
| Mar 2010 | $1.21M | Grant | – | – | |
| Sep 2008 | $1.41M | Grant | – | – | |
| Jul 2008 | $9.41M | Grant | – | – | |
| Jul 2008 | $9.41M | Grant | – | – | |
| May 2008 | $1.4M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Emmes
Emmes has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, European Union and Behrman Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm investing in buyouts of growth companies | behrmancap.com | New York, United States | ||
New Mountain Capital manages investments in private equity, credit, and net lease strategies. | newmountaincapital.com | |||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Emmes
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Emmes Services Private Limited (Emmes)
Emmes Services Private Limited is the primary company behind Emmes. The board of Emmes Services Private Limited currently have 3 directors; the longest-serving is Rama Krishna Kondru, appointed in 2024. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rama Krishna Kondru DIN 10499647 | Director | 12 Feb 2024 | 2 yrs 8 mo | Emmes Services Private Limited |
| John Matthew Bond DIN 07635517 | Director | 17 Feb 2025 | 1 yr 8 mo | Emmes Services Private Limited |
| Subhrajit Ghose DIN 10942674 | Director | 17 Feb 2025 | 1 yr 8 mo | Emmes Services Private Limited |
People of Emmes
149 people are tracked at Emmes (60 in leadership, 89 in team); the tracked headcount is 126.
| Name | Role | Group |
|---|---|---|
Amy Dwy | Associate Director, Clinical Trial Management And Monitoring | Leadership |
Megan Boyd | Director, Global Project Management | Leadership |
Antoinette Waters | Senior Human Resource Business Partner | Leadership |
Liz Richardson | Sr. Director Of Proposals | Leadership |
Ashutosh Gupta | Director Biostatistics | Leadership |
Geraldine Thomas-Monzon | Vice President Global Project Delivery | Leadership |
Courtney Nelson-Douthit | Associate Director, Global Project Management | Leadership |
Michael Ziolkowski | Vice President - Government Finance & Accounting | Leadership |
Supriya Menezes | Vice President, Ophthalmology | Leadership |
Peter Ronco | Chief Executive Officer | Leadership |
Kim Kaneshige | Sr. Director, Clinical Operations | Leadership |
Rajaram Venkatesan | Director Biostatistics | Leadership |
Jennifer McCormack | Vice President, Emmes Public Sector | Leadership |
Denise King | Vice President, Cell And Gene Therapy Operations | Leadership |
Caitlin Castle-Smith | Senior Director, Training & Development | Leadership |
Indra Prasad | Associate Director Of Software Engineering | Leadership |
Germaine Gross | Chief Commercial Officer | Leadership |
Ravinder Anand | VP, Maternal Child Health | Leadership |
Michelle Urban | Vice President, Corporate Controller | Leadership |
Georgia Rose | Director, Marketing And Communications | Leadership |
129 more people are available in the full profile.
Complete people profiles for Emmes
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Emmes
Figures of Emmes Services Private Limited, the primary company behind Emmes, for FY 2025. Revenue was ₹81.85 Cr (+40% year on year). Net profit was ₹21.56 Cr (26% margin). EBITDA was ₹30.54 Cr (37% margin). Revenue has grown at a compounded annual rate of +46% over three years and +54% over five years.
- ₹81.85 CrRevenue · FY 2025 · +40% YoY
- ₹21.56 CrNet profit · 26% margin
- ₹30.54 CrEBITDA · 37% margin
- ₹11.1 LakhPaid-up capital
- 126Employees (provident fund records)
- +46%Revenue CAGR, 3 years
- +54%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Emmes Services Private Limited are on its company page.
Detailed financial statements for Emmes
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Emmes
Emmes has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Casimir, Clinical Edge and Essex Management.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Vaccine clinical trials are managed and monitored by VaxTrials. | vaxtrials.com | Panama | 2012 | Oct 2023 | •••• | |
Provider of diversified consulting services for life science industry | essexmanagement.com | Rockville, United States | 2009 | Mar 2023 | •••• | |
CRO focused on providing drug research and development services to biology | clinicaledgeinc.com | Milwaukee, United States | 2004 | Sep 2022 | •••• | |
Clinical supply chain services are provided by CRO for trials. | casimirtrials.com | Plymouth, United States | 2016 | Mar 2022 | •••• | |
Oncology and metabolism clinical trials are supported in phases II-IV. | dr-schauerte.de | Munich, Germany | 0 | Dec 2021 | •••• | |
Rare diseases and orphan drugs development services are specialized in. | orphan-reach.com | Milton Keynes, United Kingdom | 2012 | May 2021 | •••• | |
Full-service CRO offering clinical development services from Phase I - IV and geographic focus in Central and Eastern Europe | neoxcro.com | Prague, Czech Republic | 2004 | Dec 2020 | •••• |
Complete acquisition details for Emmes
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Emmes
11 dated milestones of Emmes across 46 years, from founding to its latest funding, stage changes and deals.
- Founded Emmes is founded.
- Funding First funding round of $3.4M.
- Acquisition Acquires Neox Clinical Research.
- Acquisition Acquires Orphan Reach.
- Acquisition Acquires Institut Dr. Schauerte.
- Funding Latest funding round, Grant, of $224K.
- Acquisition Acquires Casimir.
- Exit Acquired by New Mountain Capital.
- Acquisition Acquires Clinical Edge.
- Acquisition Acquires Essex Management.
- Acquisition Acquires VaxTrials.
Competitors of Emmes
Emmes has 3 listed competitors in our database, 2 of them funded. They include Celgene, Syneos Health and Medelis WCCT Global.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| syneoshealth.com | 1984 | Raleigh, United States | 29,395 | CRO clinical development services are provided by Syneos Health. | ||
| wcct.com | 1998 | Cypress, United States | $17M | 229 | Full-service CRO expertise in influenza and oncology research is offered. |
Detailed competitors of Emmes
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Emmes
The website of Emmes (emmes.com) receives about 57.4K visits a month and ranks #665,925 among all websites worldwide, #741 in Biotechnology and Pharmaceuticals.
- Monthly visits57.4K
▲ 2% vs previous month
- Unique visitors14.8K
per month
- Global rank#665,925
among all websites
- Category rank#741
Health · Biotechnology and Pharmaceuticals
- Bounce rate59%
- Pages per visit2.0
- Average visit2 min 07 sec
- DevicesDesktop 52% · Mobile 48%
Websites whose visitors overlap most with Emmes. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| tklresearch.com | 100% | 9.5K | #4,608,578 | View details | |
ppdi.com | ppdi.com | 92% | #404,899 | – | |
| coastalcarolinaresearch.com | 84% | 5.3K | #2,256,381 | View details | |
grs-cro.com | grs-cro.com | 79% | – | ||
| washingtonbiotech.com | 77% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Emmes
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Emmes (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Emmes
Complete news archive for Emmes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emmes
Emmes was founded in 1977 and raised its 1st funding round 30 years after it was founded.
Emmes is headquartered in United States.
Emmes has 126 employees.
The primary company behind Emmes, Emmes Services Private Limited, reported revenue of ₹81.85 Cr for FY 2025, up 40% year on year.
Emmes was founded in 1977 and is headquartered in the United States. Operations focus on the healthcare sector, where clinical research services are delivered on an outsourced basis. Support is extended to pharmaceutical, biotechnology, and medical device industries through trial management, data analysis, and regulatory compliance. Activities are conducted primarily within North America, with services tailored to various therapeutic areas.
Emmes's top competitors include Syneos Health, Medelis WCCT Global and Celgene.
Emmes offers Biostatistics, Clinical Data Management, and Clinical Trial Management.
Emmes has made 7 acquisitions, including Casimir, Clinical Edge, and Essex Management.
Emmes has 4 investors. Key investors include HHS, European Union, Behrman Capital, and New Mountain Capital.
Emmes operates through Emmes Services Private Limited.
Yes. Emmes was acquired by New Mountain Capital in June 2022.
The legal entities of Emmes currently have 3 directors, including Rama Krishna Kondru, John Matthew Bond, Subhrajit Ghose.